NL7316139A - - Google Patents

Info

Publication number
NL7316139A
NL7316139A NL7316139A NL7316139A NL7316139A NL 7316139 A NL7316139 A NL 7316139A NL 7316139 A NL7316139 A NL 7316139A NL 7316139 A NL7316139 A NL 7316139A NL 7316139 A NL7316139 A NL 7316139A
Authority
NL
Netherlands
Application number
NL7316139A
Other versions
NL176168C (nl
NL176168B (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2261914A external-priority patent/DE2261914C3/de
Priority claimed from DE19732345442 external-priority patent/DE2345442C2/de
Priority claimed from DE19732351281 external-priority patent/DE2351281C3/de
Priority claimed from DE2354961A external-priority patent/DE2354961C2/de
Application filed filed Critical
Publication of NL7316139A publication Critical patent/NL7316139A/xx
Publication of NL176168B publication Critical patent/NL176168B/xx
Application granted granted Critical
Publication of NL176168C publication Critical patent/NL176168C/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NLAANVRAGE7316139,A 1972-12-18 1973-11-26 Werkwijze ter bereiding respectievelijk vervaardiging van een farmaceutisch preparaat en werkwijze ter bereiding van daarbij bruikbare nieuwe gesubstitueerde 1-(4-aminofenyl)-2-amino-ethanol-derivaten die, behalve een analgetische, uterusspasmolytische en anti-spastische werking op de dwarsgestreepte spieren, in het bijzonder een betaŸ2-mimetische en/of betaŸ1-blokkerende werking bezitten. NL176168C (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2261914A DE2261914C3 (de) 1972-12-18 1972-12-18 Amino-phenyl-äthanolamine und deren Säureadditionssalze, Verfahren zu deren Herstellung und Arzneimittel
DE19732345442 DE2345442C2 (de) 1973-09-08 1973-09-08 d- und l-Phenyläthanolamine und deren Salze, Herstellungsverfahren und Arzneimittel auf deren Basis
DE19732351281 DE2351281C3 (de) 1973-10-12 1973-10-12 Aminophenyl-äthanolamin-Derivate, deren Herstellung und Verwendung
DE2354961A DE2354961C2 (de) 1973-11-02 1973-11-02 Verfahren zur Herstellung von Aminophenyl-äthanolaminen

Publications (3)

Publication Number Publication Date
NL7316139A true NL7316139A (es) 1974-06-20
NL176168B NL176168B (nl) 1984-10-01
NL176168C NL176168C (nl) 1985-03-01

Family

ID=27431596

Family Applications (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE7316139,A NL176168C (nl) 1972-12-18 1973-11-26 Werkwijze ter bereiding respectievelijk vervaardiging van een farmaceutisch preparaat en werkwijze ter bereiding van daarbij bruikbare nieuwe gesubstitueerde 1-(4-aminofenyl)-2-amino-ethanol-derivaten die, behalve een analgetische, uterusspasmolytische en anti-spastische werking op de dwarsgestreepte spieren, in het bijzonder een betaŸ2-mimetische en/of betaŸ1-blokkerende werking bezitten.

Country Status (20)

Country Link
JP (1) JPS5811852B2 (es)
KR (1) KR850001916B1 (es)
BG (1) BG21209A3 (es)
CA (1) CA1027955A (es)
CH (2) CH605622A5 (es)
DD (1) DD111574A5 (es)
DK (1) DK150502C (es)
FI (1) FI62052C (es)
FR (1) FR2210414B1 (es)
GB (1) GB1445740A (es)
HK (1) HK6680A (es)
HU (1) HU168701B (es)
IE (1) IE39065B1 (es)
IL (1) IL43837A (es)
MY (1) MY8800145A (es)
NL (1) NL176168C (es)
NO (1) NO137782C (es)
PL (1) PL97194B1 (es)
RO (1) RO63025A (es)
SE (1) SE409700B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111148731A (zh) * 2017-09-13 2020-05-12 阿托基公司 氟苯基β-羟乙胺及其在治疗高糖血症中的用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430486A1 (fr) * 1978-07-07 1980-02-01 Oreal Conditionnement d'un produit desinfectant et desodorisant pour cuvette de toilettes
NL8105170A (nl) * 1980-12-10 1982-07-01 Thomae Gmbh Dr K Nieuwe fenylalkylaminen, werkwijze ter bereiding daarvan en de toepassing daarvan als geneesmiddelen.
FR2515177A1 (fr) * 1981-10-28 1983-04-29 Lafon Labor Nouveaux derives de 1-(aminophenyl)-2-amino-1-ethanol, leur procede de preparation et leur utilisation en therapeutique
GB8426191D0 (en) * 1984-10-17 1984-11-21 Glaxo Holdings Ltd Chemical compounds
US4943591A (en) * 1984-10-17 1990-07-24 Glaxo Group Limited Dichloroaniline derivatives
US4863959A (en) * 1985-10-17 1989-09-05 American Cyanamid Company Anthranilonitrile derivatives as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals
DE3678252D1 (de) * 1985-10-17 1991-04-25 American Cyanamid Co Anthranilonitrilderivate und verwandte verbindungen als nuetzliche stoffe zur wachstumsbeschleunigung, zur verbesserung der futterqualitaet und zur steigerung des fleisch/fett-verhaeltnisses bei warmbluetigen tieren.
GB8603475D0 (en) * 1986-02-12 1986-03-19 Glaxo Group Ltd Chemical compounds
JPS63290852A (ja) * 1987-02-10 1988-11-28 グラクソ、グループ、リミテッド 化合物
GB8703007D0 (en) * 1987-02-10 1987-03-18 Glaxo Group Ltd Chemical compounds
CN101684079B (zh) * 2003-08-29 2013-04-03 三井化学株式会社 农园艺用杀虫剂的制备中间体及制备方法
GB0604822D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders and pain
CN100497296C (zh) * 2006-07-07 2009-06-10 沈阳药科大学 旋光活性的苯乙醇胺类化合物及其制法
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111148731A (zh) * 2017-09-13 2020-05-12 阿托基公司 氟苯基β-羟乙胺及其在治疗高糖血症中的用途

Also Published As

Publication number Publication date
HK6680A (en) 1980-03-07
KR830000207A (ko) 1983-03-30
FR2210414A1 (es) 1974-07-12
RO63025A (fr) 1978-12-15
IE39065L (en) 1974-06-18
FR2210414B1 (es) 1977-01-28
FI62052C (fi) 1982-11-10
NL176168C (nl) 1985-03-01
NO137782C (no) 1978-04-26
SE409700B (sv) 1979-09-03
KR850001916B1 (ko) 1985-12-31
BG21209A3 (bg) 1976-03-20
CH605622A5 (es) 1978-10-13
PL97194B1 (pl) 1978-02-28
JPS4994640A (es) 1974-09-09
IL43837A (en) 1977-02-28
JPS5811852B2 (ja) 1983-03-04
HU168701B (es) 1976-06-28
DK150502B (da) 1987-03-16
FI62052B (fi) 1982-07-30
NO137782B (no) 1978-01-16
CA1027955A (en) 1978-03-14
CH614188A5 (en) 1979-11-15
AU6369373A (en) 1975-06-19
DD111574A5 (es) 1975-02-20
NL176168B (nl) 1984-10-01
DK150502C (da) 1987-10-26
IE39065B1 (en) 1978-08-02
IL43837A0 (en) 1974-03-14
GB1445740A (en) 1976-08-11
MY8800145A (en) 1988-12-31

Similar Documents

Publication Publication Date Title
JPS4951820A (es)
FR2210414B1 (es)
JPS499581A (es)
JPS4938434U (es)
JPS5223434B2 (es)
JPS5144384B2 (es)
JPS5245911Y2 (es)
JPS4894032A (es)
JPS5644626B2 (es)
JPS49102276U (es)
JPS4986688U (es)
JPS4998582U (es)
JPS5022620B2 (es)
CS152039B1 (es)
CS154093B1 (es)
CS154504B1 (es)
CS151834B1 (es)
CS156012B1 (es)
CS150890B1 (es)
JPS48106291U (es)
CS156329B1 (es)
JPS4949690U (es)
JPS4983000U (es)
CH1668773A4 (es)
DD112187A1 (es)

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
A85 Still pending on 85-01-01
V4 Discontinued because of reaching the maximum lifetime of a patent